TissueGen, Inc. Appoints Keith Brown as President and CEO
TissueGen, Inc. announced the appointment of Keith W. Brown as President and Chief Executive Officer. Dr. Kevin Nelson, formerly President and Chief Science Officer, will focus his efforts as Chief Science Officer. Dr. James Dukowitz, formerly Chairman and CEO, will continue to serve as Chairman of the Board. Mr. Brown will also serve on the TissueGen Board of Directors.
Dallas, TX (PRWEB) January 14, 2005 -- Mr. Brown has 15 years experience with
venture-backed biotechnology companies following 10 years in the medical
diagnostics industry. He was the founding President/CEO of GeneScreen, building
it into a $15 million, multi-location laboratory testing company in the field of
DNA analysis. GeneScreen was sold to Orchid BioSciences in 2000 where Mr. Brown
managed their Identity Genomics business to over $30 million. Mr. Brown’s
experience includes leading five rounds of venture financing with GeneScreen and
assisting in Orchid’s IPO, four acquisitions, two divestitures, and all aspects
of budgeting, financing, marketing, sales, operations and strategic business
planning.
According to Dr. Dukowitz, "The Board of Directors of TissueGen
is very pleased to have Keith Brown serve as President, Chief Executive Officer
and board member. He brings a wealth of industry and management experience to
the position, and will be essential to continuing the strong momentum and
maturation of the company at a critical point in its development.”
“I am
delighted to have Keith join TissueGen and lead its management team,” said Kevin
Nelson, Ph.D., CSO and former President of TissueGen. “He brings a valuable
combination of entrepreneurial experience and seasoned management leadership to
the company and I believe his addition will help us continue and accelerate our
transition to a commercial enterprise.”
TissueGen has received corporate
management and advisory services under a contract with Technology Innovation
Group (www.innovationmatters.com) from March 2003 until December
2004. TissueGen has recently undertaken with partners new research projects
using its proprietary technology for implantable stent applications. The company
also completed a sponsored research project using its platform drug delivery
format to validate a novel drug application. It has successfully begun its first
fund-raising, which it anticipates completing in early 2005.
About
TissueGen
TissueGen, Inc., a Delaware corporation based in Dallas, Texas, was
founded in 2000 to commercialize drug-releasing bioresorbable polymer fiber
scaffolds developed by Dr. Kevin Nelson at The University of Texas at Arlington.
TissueGen is a corporate graduate of the business incubator located at UT
Arlington. TissueGen’s proprietary technology combines drug delivery with tissue
engineering to control the timing and location of tissue growth. These fibers
are uniquely designed to meet the current challenges of tissue engineering and
drug delivery in some of the fastest growing markets, including cardiovascular
stents, advanced wound care and nerve regeneration.
The foregoing
statements are made under the "Safe Harbor" Private Securities Litigation Reform
Act of 1995 and may contain forward-looking statements that involve risks and
uncertainties that may not be evident at the time of this release. For more
information contact Keith Brown at (214) 351-1922.
# # #
Source : http://www.prweb.com/releases/2005/1/prweb196892.htm